Citations

Showing 10 of 108162 citations.

Severe Achalasia Causing Cor Pulmonale
Bayoumi, Mahmoud , Snyder, Diana L. , Menias, Christine O. , Vela, Mareclo F., Kahn, Allon

Mayo Clinic

American Journal of Gastroenterology | October 25, 2019 | Volume: 115 | Issue: 8 | Pages: 1159-1159

10.14309/ajg.0000000000000439 | PMID 31651442 Get It

Increasing Burden of Acute-On-Chronic Liver Failure Among Alcohol-Associated Liver Disease in the Young Population in the United States
Arora, Sumant, Wong, Robert J. , Satapathy, Sanjaya K. , Shah, Vijay H. , Kuo, Yong‐Fang , Kamath, Patrick S. , Sathapathy, Sanjaya , Wong, Robert J , Singal, Ashwani K.

Mayo Clinic

American Journal of Gastroenterology | October 25, 2019 | Volume: 115 | Issue: 1 | Pages: 88-95

10.14309/ajg.0000000000000411 | PMID 31651447 Get It

OBJECTIVES: Alcohol-associated liver disease is increasing, especially hospitalizations with acute on chronic liver failure and need for liver transplant. We examined trends in prevalence, inhospital mortality, and resource utilization associated with AALD and ACLF in the young. METHODS: The National Inpatient Sample (2006–2014) was queried for hospitalizations with a discharge diagnosis of cirrhosis using the International Classification of Diseases, Ninth Edition, codes. ACLF hospitalization was defined as ≥2 organ failures and stratified by age: young (≤35 years) and older (>35 years). RESULTS: Of 447,090 AALD admissions (16,126 in young) between 2006 and 2014, ACLF occurred in 29,599 (6.6%), of which 1,143 (7.1%) were in young. Compared with older, admissions in young had more women (35% vs 29%), were obese (11% vs 7.6%), were Hispanics (29% vs 18%), have alcoholic hepatitis (AH) (41% vs 17%), and have ACLF grades 2 or 3 (34% vs 25%), P < 0.001 for all. Between 2006 and 2014, ACLF in AALD among young increased from 2.8% to 5.2%, with an AH proportion from 24% to 42%, P < 0.0001 for both. Young had more complications requiring ventilation (79% vs 76%) and dialysis (32% vs 28%), P < 0.001 for both. Compared with older, ACLF admission in young had longer hospitalization (12 vs 10 days) with higher hospital charges ($127,915 vs $97,511), P < 0.0001 for both, with 20% reduced inhospital mortality (54%–45%), P < 0.001. DISCUSSION: AALD-related hospitalizations are increasing in young in the United States, mainly because of the increasing frequency of AH. Furthermore, this disease burden in young is increasing with a higher frequency of admissions with more severe ACLF and consumption of hospital resources. Studies are needed to develop preventive strategies to reduce burden related to AALD and ACLF in young.
Outcomes and Complications in the Management of Distal Radial Fractures in the Elderly
DeGeorge, Brent R. , Houten, Holly K. Van , Mwangi, Raphael , Sangaralingham, Lindsey R. , Larson, A. Noelle , Kakar, Sanjeev , Van Houten, Holly K , Larson, A Noelle , Kakar, Sanjeev

Mayo Clinic

Journal of Bone and Joint Surgery | October 25, 2019 | Volume: 102 | Issue: 1 | Pages: 37-44

10.2106/jbjs.18.00561 | PMID 31651702 Get It

Background: The purpose of the present study was to identify trends in management and to compare the outcomes and complications following nonoperative and operative management (including external fixation, closed reduction and percutaneous pinning, and open reduction and internal fixation) for distal radial fractures in patients ≥65 years of age. Methods: We performed a retrospective analysis, with use of the OptumLabs Data Warehouse database, of patients ≥65 years of age who had been managed for a distal radial fracture between 2009 and 2014 (as indicated by diagnosis codes according to the International Classification of Diseases, Ninth Revision, Clinical Modification). Ninety-day and 1-year complication rates per 1,000 fractures were analyzed overall and by treatment modality. Results: Thirteen thousand, seven hundred and thirteen distal radial fractures were analyzed. The overall 90-day complication rate was 36.5 per 1,000 fractures, and the 1-year upper-extremity-specific complication rate was 236.2 and 307.5 per 1,000 fractures for nonoperative and operative management, respectively. Overall, post-injury stiffness was the most common 1-year upper-extremity-specific complication (incidence, 11.5%). There was no significant difference between operative and nonoperative management in terms of 90-day complication rates. However, operative management had a higher 1-year complication rate than nonoperative management (307.5 versus 236.2 per 1,000 fractures). Overall, the 5 most common upper-extremity-specific complications following operative treatment of distal radial fracture were stiffness (16.0%), chronic regional pain syndrome (9.9%), median neuropathy (8.0%), implant-related complications (3.8%), and tendon-related complications (2.8%). Stiffness was significantly more frequent following operative management (16.0% versus 9.8%; p < 0.01). Conclusions: Operative management of a distal radial fracture should be carefully considered when discussing treatment options with patients ≥65 years of age. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Whipworm Found During a Colonoscopy
Eaton, John E. , Wang, Xiao‐Jing

Mayo Clinic

ACG Case Reports Journal | October 25, 2019 | Volume: 6 | Issue: 10 | Pages: e00259

10.14309/crj.0000000000000259 | PMID 31832477 Get It

Anesthesia With and Without Nitrous Oxide and Long-term Cognitive Trajectories in Older Adults
Abcejo, Arnoley S., Petersen, Ronald C. , Hanson, Andrew C. , Schroeder, Darrell R. , Schulte, Phillip J. , Martin, David P. , Pasternak, Jeffrey J., Schroeder, Darrell , Šprung, Juraj , Knopman, David S. , Mielke, Michelle M. , Weingarten, Toby N. , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | October 25, 2019 | Volume: 131 | Issue: 2 | Pages: 594-604

10.1213/ane.0000000000004490 | PMID 31651458 Get It

BACKGROUND: We evaluated the hypothesis that the rate of postoperative decline in global cognition is greater in older adults exposed to general anesthesia with nitrous oxide (N 2 O) compared to general anesthesia without N 2 O. METHODS: Longitudinal measures of cognitive function were analyzed in nondemented adults, 70–91 years of age, enrolled in the Mayo Clinic Study of Aging. Linear mixed-effects models with time-varying covariates assessed the relationship between exposure to surgery with general anesthesia (surgery/GA) with or without N 2 O and the rate of long-term cognitive changes. Global cognition and domain-specific cognitive outcomes were defined using z scores, which measure how far an observation is, in standard deviations, from the unimpaired population mean. RESULTS: The analysis included 1819 participants: 280 exposed to GA without N 2 O following enrollment and before censoring during follow-up (median [interquartile range {IQR}] follow-up of 5.4 [3.9–7.9] years); 256 exposed to GA with N 2 O (follow-up 5.6 [4.0–7.9] years); and 1283 not exposed to surgery/GA (follow-up 4.1 [2.5–6.4] years). The slope of the global cognitive z score was significantly more negative following exposure to surgery/GA after enrollment (change in slope of −0.062 [95% confidence interval {CI}, −0.085 to −0.039] for GA without N 2 O, and −0.058 [95% CI, −0.080 to −0.035] for GA with N 2 O, both P < .001). The change in slope following exposure to surgery/GA did not differ between those exposed to anesthesia without versus with N 2 O (estimated difference −0.004 [95% CI, −0.035 to 0.026], P = .783). CONCLUSIONS: Exposure to surgery/GA is associated with a small, but statistically significant decline in cognitive z scores. Cognitive decline did not differ between anesthetics with and without N 2 O. This finding provides evidence that the use of N 2 O in older adults does not need to be avoided because of concerns related to decline in cognition.
A decreased abundance of clostridia characterizes the gut microbiota in eosinophilic esophagitis
Kashyap, Purna , Johnson, Stephen , Geno, Debra M., Lekatz, Heather, Lavey, Crystal, Alexander, Jeffrey A. , Katzka, David A. , Lekatz, Heather R, Katzka, D A , Chen, Jun

Mayo Clinic

Physiological Reports | October 25, 2019 | Volume: 7 | Issue: 20 | Pages: No page available

10.14814/phy2.14261 | PMID 31650712 Get It

Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology
Polley, Mei‐Yin C. , Cheung, Ying Kuen

Mayo Clinic

JCO Precision Oncology | October 24, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-8

10.1200/po.19.00057 | PMID 32923846 Get It

Applications in early-phase cancer trials have motivated the development of many statistical designs since the late 1980s, including dose-finding methods, futility screening, treatment selection, and early stopping rules. These methods are often proposed to address the conventional cytotoxic therapeutics for neoplastic diseases and cancer. Recent advances in precision medicine have motivated novel trial designs, most notably the idea of master protocol (eg, platform trial, basket trial, umbrella trial, N-of-1 trial), for the evaluation of molecularly targeted cancer therapies. In this article, we review the concepts and methodology of early-phase cancer trial designs with a focus on dose finding and treatment screening and put these methods in the context of platform trials of molecularly targeted cancer therapies. Because most cancer trial designs have been developed for cytotoxic agents, we will discuss how these time-tested design principles hold relevance for targeted cancer therapies, and we will delineate how a master protocol may serve as an efficient platform for safety and efficacy evaluations of novel targeted therapies.
Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies
An, Ming‐Wen , Ruppert, Amy S. , Mandrekar, Sumithra J. , Ou, Fang‐Shu

Mayo Clinic

JCO Precision Oncology | October 24, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-10

10.1200/po.19.00051 | PMID 32190807 Get It

With the launch of the National Cancer Institute’s Precision Medicine Initiative in 2015, there has been a shift to trial designs that tailor health care solutions to individual patients by using a screening platform and by moving away from the one-trial/one-biomarker-at-a-time approach. To make precision medicine a reality, it is critical to identify and validate potential biomarkers to help select patients who will truly benefit from a targeted therapy. In this article, we discuss five trial designs: enrichment, umbrella, basket, subgroup, and window of opportunity. For each trial design, we describe the design characteristics, use ongoing or completed trials as case studies, provide any recent advances to the trial design, and discuss advantages and disadvantages of each design.
Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation
Polley, Mei‐Yin C. , Korn, Edward L. , Freidlin, Boris

Mayo Clinic

JCO Precision Oncology | October 24, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-9

10.1200/po.18.00416 | PMID 32923845 Get It

Recent advances in biotechnology and cancer genomics have afforded enormous opportunities for development of more effective anticancer therapies. A key thrust of this modern drug development paradigm is successful identification of predictive biomarkers that can distinguish patients who might be sensitive to new targeted therapies. To respond to this challenge, a number of phase III cancer trial designs integrating biomarker-based objectives have been proposed and implemented in oncology drug development. In this article, we provide an updated review of commonly used biomarker-based randomized clinical trial designs, with a particular focus on design efficiency. When the efficacy of a new therapy may be limited to a biomarker-defined subgroup, the choice of an appropriate randomized clinical trial design should be guided by the strength of the biomarker’s credentials. If compelling evidence indicates that a targeted therapy is beneficial only in a particular biomarker-defined subgroup, an enrichment design should be used. If there is strong evidence that the treatment is likely to be more beneficial in the biomarker-positive patients but a meaningful benefit is also possible in the biomarker-negative patients, then a properly powered biomarker-stratified design (eg, a subgroup-specific or Marker Sequential Test strategy) would provide the most rigorous determination of the sensitive populations. If the evidence supporting the predictive value of the biomarker is weak and the treatment is expected to work in the overall population, then a fallback design could be used. Careful selection of an appropriate phase III design strategy that integrates evaluation of a new anticancer therapy and its companion diagnostic is critical to the success of precision medicine in oncology.
Dissociating the effects of oxygen pressure and content on the control of breathing and acute hypoxic response
Dominelli, Paolo B. , Baker, Sarah E. , Wiggins, Chad C. , Stewart, Glenn M. , Sajgalik, Pavol , Shepherd, John R. A. , Roberts, Shelly K., Roy, Tuhin K. , Curry, Timothy B. , Hoyer, James D., Oliveira, Jennifer L. , Herrick, Jennifer L. , Foster, Glen E , Wiggins, Chad C , Roy, Tuhin K , Baker, Sarah E , Foster, Glen E. , Joyner, Michael J.

Mayo Clinic

Journal of Applied Physiology | October 24, 2019 | Volume: 127 | Issue: 6 | Pages: 1622-1631

10.1152/japplphysiol.00569.2019 | PMID 31647724 Get It

Arterial oxygen tension and oxyhemoglobin saturation ([Formula: see text]) decrease in parallel during hypoxia. Distinguishing between changes in oxygen tension and oxygen content as the relevant physiological stimulus for cardiorespiratory alterations remains challenging. To overcome this, we recruited nine individuals with hemoglobinopathy manifesting as high-affinity hemoglobin [HAH; partial pressure at 50% [Formula: see text] (P50) = 16 ± 0.4 mmHg] causing greater [Formula: see text] at a given oxygen partial pressure compared with control subjects ( n = 12, P50 = 26 ± 0.4 mmHg). We assessed ventilatory and cardiovascular responses to acute isocapnic hypoxia, iso-oxic hypercapnia, and 20 min of isocapnic hypoxia (arterial Po2 = 50 mmHg). Blood gas alterations were achieved with dynamic end-tidal forcing. When expressed as a function of the logarithm of oxygen partial pressure, ventilatory sensitivity to hypoxia was not different between groups. However, there was a significant difference when expressed as a function of [Formula: see text]. Conversely, the rise in heart rate was blunted in HAH subjects when expressed as a function of partial pressure but similar when expressed as a function of [Formula: see text]. Ventilatory sensitivity to hypercapnia was not different between groups. During sustained isocapnic hypoxia, the rise in minute ventilation was similar between groups; however, heart rate was significantly greater in the controls during 3 to 9 min of exposure. Our results support the notion that oxygen tension, not content, alters cellular Po2in the chemosensors and drives the hypoxic ventilatory response. Our study suggests that in addition to oxygen partial pressure, oxygen content may also influence the heart rate response to hypoxia.NEW & NOTEWORTHY We dissociated the effects of oxygen content and pressure of cardiorespiratory regulation studying individuals with high-affinity hemoglobin (HAH). During hypoxia, the ventilatory response, expressed as a function of oxygen tension, was similar between HAH variants and controls; however, the rise in heart rate was blunted in the variants. Our work supports the notion that the hypoxic ventilatory response is regulated by oxygen tension, whereas cardiovascular regulation may be influenced by arterial oxygen content and tension.